Peter Ettmayer
Vienna, 1221, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Targeting cancer with small-molecule pan-KRAS degraders.
Journal: Science (New York, N.Y.)
Published: September 19, 2024
Chasing Red Herrings: Palladium Metal Salt Impurities Feigning KRAS Activity in Biochemical Assays.
Journal: Journal of medicinal chemistry
Published: July 15, 2024
opnMe.com: a digital initiative for sharing tools with the biomedical research community.
Journal: Nature reviews. Drug discovery
Published: April 23, 2022
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling.
Journal: Nature cancer
Published: July 27, 2021
One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS.
Journal: Journal of medicinal chemistry
Published: March 15, 2021
The Kinase Chemogenomic Set (KCGS): An Open Science Resource for Kinase Vulnerability Identification.
Journal: International journal of molecular sciences
Published: December 08, 2020
BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition.
Journal: Cancer discovery
Published: February 06, 2020
Native Mass Spectrometry Can Effectively Predict PROTAC Efficacy.
Journal: ACS central science
Published: January 15, 2020
Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors.
Journal: Journal of medicinal chemistry
Published: November 06, 2019
Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance.
Journal: Molecular cancer therapeutics
Published: August 12, 2019
Intracellular Trapping of the Selective Phosphoglycerate Dehydrogenase (PHGDH) Inhibitor BI-4924 Disrupts Serine Biosynthesis.
Journal: Journal of medicinal chemistry
Published: August 01, 2019
Last Updated: 09/26/2026